Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

22 mai 2018 20h05 HE | Source: MyoKardia, Inc.

MyoKardia Announces Pricing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., May 22, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of...
21 mai 2018 16h01 HE | Source: MyoKardia, Inc.

MyoKardia Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., May 21, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of...
21 mai 2018 07h30 HE | Source: MyoKardia, Inc.

MyoKardia Announces Design of Phase 3 EXPLORER-HCM Study Evaluating Mavacamten in Symptomatic, Obstructive Hypertrophic Cardiomyopathy

Single Pivotal to Support Registration; Target Enrollment of 220 Patients; Primary Endpoint of Clinical Response Using Peak VO2 and NYHA Classification Improvements Expected to Initiate in Second...
10 mai 2018 16h30 HE | Source: MyoKardia, Inc.

MyoKardia to Present at the Bank of America Merrill Lynch 2018 Health Care Conference

SOUTH SAN FRANCISCO, Calif., May 10, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of...
10 mai 2018 08h30 HE | Source: MyoKardia, Inc.

MyoKardia Doses First Patient in PIONEER Open-Label Extension Study of Mavacamten for Symptomatic, Obstructive Hypertrophic Cardiomyopathy

SOUTH SAN FRANCISCO, Calif., May 10, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of...
08 mai 2018 16h01 HE | Source: MyoKardia, Inc.

MyoKardia Reports First Quarter 2018 Financial Results

Company to Host Conference Call and Webcast Today at 4:30 p.m. ET (1:30 p.m. PT) SOUTH SAN FRANCISCO, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage...
03 mai 2018 16h01 HE | Source: MyoKardia, Inc.

MyoKardia to Report First Quarter 2018 Financial Results on Tuesday, May 8, 2018

SOUTH SAN FRANCISCO, Calif., May 03, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of...
04 avr. 2018 08h30 HE | Source: MyoKardia, Inc.

MyoKardia Announces Appointment of Taylor C. Harris as Chief Financial Officer

SOUTH SAN FRANCISCO, Calif., April 04, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment...
02 avr. 2018 08h30 HE | Source: MyoKardia, Inc.

MyoKardia Begins Dosing in Phase 2 MAVERICK-HCM Clinical Trial of Mavacamten in Symptomatic Non-obstructive Hypertrophic Cardiomyopathy Patients

SOUTH SAN FRANCISCO, Calif., April 02, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment...
08 mars 2018 16h03 HE | Source: MyoKardia, Inc.

MyoKardia Reports Fourth Quarter and Full Year 2017 Financial Results

Announced Achievement of Primary Endpoint and Additional Key Data from Low-Dose Mavacamten Cohort of PIONEER-HCM Phase 2 Study in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Company to Host...

Page précédente